Alkermes (ALKS) R&D chief exercises 5,000 options and sells 9,000 shares

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported a combination of option exercise and share sales in Ordinary Shares. He exercised employee stock options for 5,000 shares at a conversion price of $19.34 per share and, on the same date, sold a total of 9,000 Ordinary Shares in open-market transactions at weighted average prices of $51.4613 and $52.1314. The filing notes these transactions were executed under a Rule 10b5-1 trading plan adopted on March 14, 2025. Following the transactions, he directly holds 82,389 Ordinary Shares and 1,356 employee stock options.

Insights

Routine 10b5-1 option exercise and net share sale by Alkermes executive.

The reporting person exercised 5,000 employee stock options at a conversion price of $19.34 per share, then sold 9,000 Ordinary Shares in open-market trades at weighted average prices of $51.4613 and $52.1314. This pattern is typical of using vested options to generate liquidity.

Footnotes state both the option exercise and share sales occurred pursuant to a Rule 10b5-1 trading plan adopted on March 14, 2025, indicating the trades were pre-planned rather than opportunistic. After these moves, the executive still holds 82,389 Ordinary Shares and 1,356 options, so the transactions represent a partial adjustment, not an exit.

Insider Trade Summary 10b5-1

Net Seller: 9,000 shares ($463,621)

Net Sell 4 txns

Insider Hopkinson Craig C.

Role EVP R&D, Chief Medical Officer

Sold 9,000 shs ($464K)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Buy)	5,000	$0.00	--
Exercise	Ordinary Shares	5,000	$19.34	$97K
Sale	Ordinary Shares	8,300	$51.4613	$427K
Sale	Ordinary Shares	700	$52.1314	$36K

Holdings After Transaction: Employee Stock Option (Right to Buy) — 1,356 shares (Direct, null); Ordinary Shares — 82,389 shares (Direct, null)

Footnotes (1)

This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.06 to $52.04. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.10 to $52.17. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. These options are fully vested in accordance with their terms.

Key Figures

Shares sold: 9,000 shares Weighted average sale price (block 1): $52.1314 per share Weighted average sale price (block 2): $51.4613 per share +5 more

8 metrics

Shares sold 9,000 shares Ordinary Shares sold in open-market transactions on 2026-07-01

Weighted average sale price (block 1) $52.1314 per share 700 Ordinary Shares sold; multiple trades from $52.10 to $52.17

Weighted average sale price (block 2) $51.4613 per share 8,300 Ordinary Shares sold; multiple trades from $51.06 to $52.04

Options exercised 5,000 shares Employee Stock Option (Right to Buy) converted into Ordinary Shares

Option exercise price $19.34 per share Conversion price for 5,000 options exercised

Shares held after transactions 82,389 Ordinary Shares Direct holdings following reported trades

Options remaining 1,356 options Employee Stock Options remaining after 5,000-share exercise

Rule 10b5-1 plan adoption date March 14, 2025 Covers both the option exercise and share sales

Key Terms

Rule 10b5-1 trading plan, weighted average price, Employee Stock Option (Right to Buy), Ordinary Shares, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Employee Stock Option (Right to Buy) financial

"Security title: Employee Stock Option (Right to Buy)"

Ordinary Shares financial

"Security title: Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 06:29 PM Accepted by SEC EDGAR 07/01/2026 - 06:29 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopkinson Craig C.

(Last)

(First)

(Middle)

900 WINTER STREET

(Street)

WALTHAM

MASSACHUSETTS

02451

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alkermes plc. [ ALKS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP R&D, Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	07/01/2026		M⁽¹⁾		5,000	A	$19.34	82,389	D
Ordinary Shares	07/01/2026		S⁽²⁾		8,300	D	$51.4613⁽³⁾	74,089	D
Ordinary Shares	07/01/2026		S⁽²⁾		700	D	$52.1314⁽⁴⁾	73,389	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (Right to Buy)	$19.34	07/01/2026		M⁽¹⁾			5,000	⁽⁵⁾	02/22/2031	Ordinary Shares	5,000	$0	1,356	D

Explanation of Responses:

1. This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.06 to $52.04. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.10 to $52.17. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

5. These options are fully vested in accordance with their terms.

	/s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Alkermes (ALKS) report for Craig C. Hopkinson?

Craig C. Hopkinson reported exercising 5,000 employee stock options and selling 9,000 Alkermes Ordinary Shares. The transactions occurred on the same date and involved open-market sales at weighted average prices around the low $50 range, according to the Form 4.

At what prices did Craig C. Hopkinson sell Alkermes (ALKS) shares?

He sold 700 Ordinary Shares at a weighted average price of $52.1314 and 8,300 shares at $51.4613. Footnotes explain these were multiple trades in ranges from $51.06 to $52.17, grouped as weighted average prices in the disclosure.

How many Alkermes (ALKS) shares does Craig C. Hopkinson hold after this Form 4?

After the reported transactions, Craig C. Hopkinson directly holds 82,389 Ordinary Shares of Alkermes. The filing also shows he retains 1,356 employee stock options, indicating he remains a significant equity holder following the option exercise and share sales.

Were Craig C. Hopkinson’s Alkermes (ALKS) trades under a Rule 10b5-1 plan?

Yes. Footnotes state both the option exercise and related share sales were effected pursuant to a Rule 10b5-1 trading plan adopted on March 14, 2025. Such plans pre-schedule trades, suggesting these transactions were part of a pre-arranged liquidity program.

What type of options did Craig C. Hopkinson exercise in Alkermes (ALKS)?

He exercised an Employee Stock Option (Right to Buy) covering 5,000 underlying Ordinary Shares at a conversion price of $19.34 per share. A footnote confirms these options were fully vested in accordance with their terms at the time of exercise.

What is the net effect of Craig C. Hopkinson’s Alkermes (ALKS) transactions?

The net effect is a 9,000-share reduction in his Ordinary Share holdings alongside the exercise of 5,000 options. He continues to hold 82,389 Ordinary Shares and 1,356 options, so the filing reflects portfolio rebalancing and liquidity rather than a complete position exit.